Journal of vascular and interventional radiology : JVIR · 2026
A Systematic Review and Meta-Analysis Comparing Perioperative and Patency Outcomes of Aortoiliac Kissing Stents versus Aortic Bifurcated Bypass for Trans-Atlantic Inter-Society Consensus Document on Management of Peripheral Arterial Disease II C/D Aortoiliac Occlusive Disease.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fernandez Miguel Godeiro, Pimentel-Junior Dilson, Bertolino Enrico Prajiante, Mastra Milena Monteiro, Obara Mariana Kondo, Filippini Denise, B Melo Carlos, D'Oria Mario, Mulatti Grace Carvajal
Аннотация
PURPOSE: To perform a meta-analysis comparing perioperative (30-day mortality, length of hospital stay, and acute kidney injury) and patency outcomes (primary, assisted primary, secondary, and freedom from reintervention) of aortoiliac kissing stents (KSs) versus aortic bifurcated bypass surgery (ABBS) in patients with Trans-Atlantic Inter-Society Consensus Document on Management of Peripheral Arterial Disease II (TASC-II) C/D aortoiliac occlusive disease (AIOD).
MATERIALS AND METHODS: MEDLINE, Embase, and Cochrane databases were searched from inception through June 2025. Inclusion was restricted to original studies comparing KS versus ABBS for TASC-II C/D AIOD with reported perioperative and patency outcomes. Pooled odds ratios (ORs), mean differences (MDs), and hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using a random-effects model.
RESULTS: Four cohort studies involving 385 patients (215 with KS and 170 with ABBS) were included. No significant difference was observed between KS and ABBS groups in 30-day mortality (OR, 1.37; 95% CI, 0.04-49.96; P = .86) and acute kidney injury (OR, 0.65; 95% CI, 0.16-2.62; P = .54). KS was associated with a significantly shorter hospital stay (MD, -5.92 days; 95% CI, -8.47 to -3.36; P < .00001). Rates of primary patency (HR, 1.49; 95% CI, 0.25-8.96; P = .66), assisted primary patency (HR, 0.75; 95% CI, 0.08-6.74; P = .80), secondary patency (HR, 0.86; 95% CI, 0.13-5.69; P = .88), and freedom from reintervention (HR, 2.66; 95% CI, 0.52-13.66; P = .24) were similar between the compared interventions during follow-up.
CONCLUSIONS: KS and ABBS demonstrate comparable patency and perioperative outcomes for TASC-II C/D AIOD.
MATERIALS AND METHODS: MEDLINE, Embase, and Cochrane databases were searched from inception through June 2025. Inclusion was restricted to original studies comparing KS versus ABBS for TASC-II C/D AIOD with reported perioperative and patency outcomes. Pooled odds ratios (ORs), mean differences (MDs), and hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using a random-effects model.
RESULTS: Four cohort studies involving 385 patients (215 with KS and 170 with ABBS) were included. No significant difference was observed between KS and ABBS groups in 30-day mortality (OR, 1.37; 95% CI, 0.04-49.96; P = .86) and acute kidney injury (OR, 0.65; 95% CI, 0.16-2.62; P = .54). KS was associated with a significantly shorter hospital stay (MD, -5.92 days; 95% CI, -8.47 to -3.36; P < .00001). Rates of primary patency (HR, 1.49; 95% CI, 0.25-8.96; P = .66), assisted primary patency (HR, 0.75; 95% CI, 0.08-6.74; P = .80), secondary patency (HR, 0.86; 95% CI, 0.13-5.69; P = .88), and freedom from reintervention (HR, 2.66; 95% CI, 0.52-13.66; P = .24) were similar between the compared interventions during follow-up.
CONCLUSIONS: KS and ABBS demonstrate comparable patency and perioperative outcomes for TASC-II C/D AIOD.